sing a high-power thulium laser system in the operation to treat benign prostate hyperplasia
Completed
- Conditions
- Urological and Genital Diseasesrinary frequency, nocturia, weak stream, or urine retention
- Registration Number
- ISRCTN52339705
- Lead Sponsor
- Taipei Veterans General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 35
Inclusion Criteria
1. International prostate symptom score (IPSS) >7
2. Maximum urinary flow rate (Qmax) <15 mL/s
3. Normal level of age-specific prostate-specific antigen (PSA)
4. Patients with abnormal levels of age-specific PSA or positive findings on digital rectal examination underwent transrectal ultrasonography (TRUS)-guided biopsy to rule out prostate cancer. Ten patients underwent TRUS-guided biopsy before the operation
Exclusion Criteria
Prostate cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Operative variables obtained before the operation <br>2. Patient profiles obtained before the operation<br>3. Urine flow rates obtained before the operation and at 3, 6, 9 and 12 months after the operation<br>4. Prostate volume (measured using transrectal ultrasonography) obtained before the operation and at 3, 6, 9 and 12 months after the operation<br>5. International prostate symptom score (IPSS) via questionnaires obtained before the operation and at 3, 6, 9 and 12 months after the operation<br>
- Secondary Outcome Measures
Name Time Method 1. Urine flow rates obtained at 6, 9 and 12 months after the operation<br>2. Prostate volume (measured using transrectal ultrasonography) obtained at 6, 9 and 12 months after the operation<br>3. International prostate symptom score (IPSS) via questionnaires obtained at 6, 9 and 12 months after the operation